



## Introduction


Immunized animals are still a key source for antibodies generated within therapeutic campaigns to obtain high affinity antibody drug candidates. Therefore, humanization and de-risking of these antibodies is an important antibody engineering step in the development of therapeutic antibodies. However, humanization is still characterized by a high risk as affinity and specificity can be lost during the humanization process. Therefore, ImmunoPrecise (formerly ModiQuest) developed a full antibody engineering platform (ModiTune™) to obtain humanized antibodies with similar affinity and specificity as the original antibody.

## Methods & Results


### Phase I



### Phase II



### Phase III



## Conclusions

IPA's ModiTune™ humanization approach resulted in the humanization of a mouse antibody without affinity and specificity loss and the selection of 3 fully characterized therapeutic lead candidates to be taken forward into pre-clinical studies in less than a year.